NASDAQ: ESPREsperion Therapeutics Inc Stock
$2.20+0.05 (+2.33%)
Updated Jan 22, 2025
ESPR Price
$2.20
Fair Value Price
N/A
Market Cap
$433.48M
52 Week Low
$1.58
52 Week High
$3.94
P/E
-3.55x
P/B
-1.17x
P/S
1.09x
PEG
N/A
Dividend Yield
N/A
Revenue
$295.45M
Earnings
-$86.77M
Gross Margin
81.6%
Operating Margin
-9.78%
Profit Margin
-29.4%
Debt to Equity
-1.85
Operating Cash Flow
-$26M
Beta
0.97
Next Earnings
Feb 25, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ESPR Overview
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ESPR's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Value
B
Growth
C
Momentum
C
Sentiment
C
Safety
C
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
ESPR
Ranked#27 of 61
Ranked#27 of 61
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $38.17 | A | |
| $21.76 | A | |
| $14.66 | A |
Be the first to know about important ESPR news, forecast changes, insider trades & much more!
ESPR News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ESPR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ESPR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ESPR is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
ESPR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more ESPR due diligence checks available for Premium users.
Valuation
ESPR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.55x
Industry
4.47x
Market
30.67x
ESPR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.17x
Industry
2.26x
ESPR's financial health
Profit margin
Revenue
$51.6M
Net Income
-$29.5M
Profit Margin
-57.2%
ESPR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ESPR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$314.1M
Liabilities
$684.3M
Debt to equity
-1.85
ESPR's short-term assets ($307.56M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ESPR's long-term liabilities ($518.45M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ESPR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ESPR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$35.3M
Investing
-$167.0k
Financing
-$9.1M
ESPR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ESPR vs Pharmaceutical Stocks
Esperion Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.